Actinium Pharmaceuticals
ATNM
30 hedge funds and large institutions have $5.2M invested in Actinium Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
234% more call options, than puts
Call options by funds: $234K | Put options by funds: $70K
25% more funds holding
Funds holding: 24 → 30 (+6)
0.01% more ownership
Funds ownership: 0.2% → 0.21% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
36% less capital invested
Capital invested by funds: $8.12M → $5.2M (-$2.92M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$414K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$168K |
| 3 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$84.2K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$53.5K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$42.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$236K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$47.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$46.7K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$34K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$15.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Group One Trading
Chicago,
Illinois
| $2K | -$15.3K | -243 | -88% |
|
|
AIM
27
Acrospire Investment Management
Chicago,
Illinois
| $2K | +$2.34K | +37 | New |
|
28
Geode Capital Management
Boston,
Massachusetts
| $301 | – | – | – |
|
|
29
Balyasny Asset Management
Chicago,
Illinois
| – | -$34K | -352 | Closed |
|
30
JP Morgan Chase
New York
| – | +$189 | +3 | New |
|
31
Citigroup
New York
| – | +$253 | +4 | New |
|
ATNM Hedge Fund Activity: Q1 2016 in Review
30 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2016, worth a combined $5.2M — down 36% from $8.12M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ATNM positions and 1 closed out — a net gain of 6 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $414K. The largest seller was Oxford Asset Management, cutting an estimated $236K.
- 30 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2016, up from 24 in Q4 2015.
- Funds reported $5.2M of Actinium Pharmaceuticals stock for Q1 2016, down 36% quarter-over-quarter.
- 7 funds opened new Actinium Pharmaceuticals positions in Q1 2016 and 1 closed out, a net change of +6 holders.
- The largest Actinium Pharmaceuticals buyer in Q1 2016 was Vanguard Group, an estimated $414K added.
- The largest Actinium Pharmaceuticals seller in Q1 2016 was Oxford Asset Management, an estimated $236K sold.
Based on aggregated 13F filings for Q1 2016.